Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants
Issued Date
2024-01-01
Resource Type
ISSN
03065251
eISSN
13652125
Scopus ID
2-s2.0-85195601963
Journal Title
British Journal of Clinical Pharmacology
Rights Holder(s)
SCOPUS
Bibliographic Citation
British Journal of Clinical Pharmacology (2024)
Suggested Citation
Banda C.G., Tarning J., Barnes K.I. Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants. British Journal of Clinical Pharmacology (2024). doi:10.1111/bcp.16132 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/98871
Title
Use of population pharmacokinetic-pharmacodynamic modelling to inform antimalarial dose optimization in infants
Author(s)
Corresponding Author(s)
Other Contributor(s)
Abstract
Infants bear a significant malaria burden but are usually excluded from participating in early dose optimization studies that inform dosing regimens of antimalarial therapy. Unlike older children, infants' exclusion from early-phase trials has resulted in limited evidence to guide accurate dosing of antimalarial treatment for uncomplicated malaria or malaria-preventive treatment in this vulnerable population. Subsequently, doses used in infants are often extrapolated from older children or adults, with the potential for under- or overdosing. Population pharmacokinetic-pharmacodynamic (PK-PD) modelling, a quantitative methodology that applies mathematical and statistical techniques, can aid the design of clinical studies in infants that collect sparse pharmacokinetic data as well as support the analysis of such data to derive optimized antimalarial dosing in this complex and at-risk yet understudied subpopulation. In this review, we reflect on what PK-PD modelling can do in programmatic settings of most malaria-endemic areas and how it can be used to inform antimalarial dose optimization for preventive and curative treatment of uncomplicated malaria in infants. We outline key developmental physiological changes that affect drug exposure in early life, the challenges of conducting dose optimization studies in infants, and examples of how PK-PD modelling has previously informed antimalarial dose optimization in this subgroup. Additionally, we discuss the limitations and gaps of PK-PD modelling when used for dose optimization in infants. To utilize modelling well, there is a need to generate useful, sparse, PK and PD data in this subpopulation to inform antimalarial optimal dosing in infancy.